Outcome in AIDS-Related Systemic Non-Hodgkin Lymphoma and Leptomeningeal Disease Is Not Predicted by a CT Brain Scan

References

1. ↵
   Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–60

   CrossRefPubMedWeb of Science
2. ↵
   Stebbing J, Bower M. What can oncologists learn from HIV? Lancet Oncol 2003;4:438–45

   CrossRefPubMedWeb of Science
3. ↵
   Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004;22:2177–83

   Abstract/FREE Full Text
4. ↵
   Stebbing J, Marvin V, Bower M. The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma. Cancer Treat Rev 2004;30:249–53

   CrossRefPubMedWeb of Science
5. ↵
   Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005;143:265–73

   CrossRefPubMedWeb of Science
6. ↵
   Abrey LE. Leptomeningeal noplasms. Curr Treat Options Neurol 2002;4:147–56

   CrossRefPubMed
7. ↵
   Sarker D, Thirlwell C, Nelson M, et al. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS 2003;17:861–65

   CrossRefPubMedWeb of Science
8. ↵
   Gleissner B, Siehl J, Korfel A, et al. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002;58:390–96

   Abstract/FREE Full Text
9. ↵
   Kremer S, Abu Eid M, Bierry G, et al. Accuracy of delayed post-contrast FLAIR MR imaging for the diagnosis of leptomeningeal infectious or tumoral diseases. J Neuroradiol 2006;33:285–91

   PubMed
10. ↵
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81

    CrossRefWeb of Science
11. ↵
    Peto R, Pike M, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 1977;35:1–39

    CrossRefPubMedWeb of Science
12. ↵
    A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–94

    CrossRefPubMedWeb of Science
13. ↵
    Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430–38

    Abstract/FREE Full Text